Deals
J&J's Still Mulling Acquisitions Amid $10 Billion Share Buyback
- Analysts and investors see value in smaller deals for J&J
- J&J could look at purchases of drug or medical device makers
Inside Johnson & Johnson's Earnings Beat
This article is for subscribers only.
Johnson & Johnson executives, embarking on a $10 billion share buyback program, emphasized Tuesday they still have the cash and the appetite for deals.
"I wouldn’t interpret the $10 billion share buyback as impacting our appetite for scale of any size in M&A at all," Chief Financial Officer Dominic Caruso said on a conference call Tuesday. "Our appetite for M&A of any scale has entirely to do with whether or not the acquisition is going to create value for shareholders."